Characteristics of Oral Mucosal Events Related to Bevacizumab Treatment

BACKGROUND. Bevacizumab, a monoclonal antibody targeting a vascular endothelial growth factor (VEGF) protein, has been reported to induce mucosal toxicities. However, the clinical characteristics of these particular toxicities have not been well characterized. We aimed at providing a detailed clinic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gavrilovic, Igor T., Balagula, Yevgeniy, Rosen, Alyx C., Ramaswamy, Vijay, Dickler, Maura N., Dunkel, Ira J., Lacouture, Mario E.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2012
Assuntos:
Symptom Management and Supportive Care
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3286177/
https://ncbi.nlm.nih.gov/pubmed/22282905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0198
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados